ETF name(Code), Benchmark Index, Inception date, creation unit, Net Asset (KRW 0.1 billion), Trustee, Rule of Dividend payment, Market Price per share (KRW), iNAV per share (KRW), trading volume (share), Total Expense ratio table
ETF Name (code)
Benchmark Index
Inception date
Creation Unit
AUM (KRW)
KB RISE HealthCare Fixed Income Balanced ETF
(253290)
FnGuide HealthCare Mix Index
2016.09.23
200,000
14,747,489,387
Trustee
Market Price per share (KRW)
NAV
Trading Volume (shares)
하나은행
12,235
※ t-1 last price
12,289
16,729
authorized participant, Liquidity provider table
Total Expense Ratio
Distribution Frequency
Year 0.35%
(Designated participating company : 0.001%,
Collective investment : 0.309%,
trust : 0.02%,
General affairs : 0.02%)
Based on the business day before the interest payment date of the stocks constituting the index in June and December (occasional payment)
The FnGuide Healthcare Balanced Index is an index consisting of stock items constituting the FnGuide Healthcare Index and three KTBs constituting the MKF 3-year KTB Index. It maintains a 7:3 ratio of bonds to stocks everyday.
Name, Ticker, Number. of shares, Weight(%), market price (KRW)
No. (Number)
Name
Ticker
Number of shares
Weight(%)
Market price (KRW)
1
KTB03000-2909(24-7)
KR103501GE98
666,666,666
27.91
687,639,999
2
KTB02875-2712(24-12)
KR103501GEC6
500,000,000
20.64
508,476,000
3
RISE HealthCare
KR7253280002
20,641
12.28
302,597,060
4
RISE KTB
KR7114100001
1,900
8.52
209,798,000
5
KTB03250-2706(24-4)
KR103501GE64
166,666,667
6.92
170,439,167
6
원화예금
KRD010010001
99,820,764
4.05
99,820,764
7
F 202509
KR4165W90002
0.67
2.91
71,586,702
8
Celltrion
KR7068270008
294
2.06
50,685,600
9
Alteogen
KR7196170005
117
1.99
48,906,000
10
SAMSUNG BIOLOGICS
KR7207940008
47
1.93
47,564,000
11
Yuhan
KR7000100008
392
1.83
45,197,600
12
PharmaResearch
KR7214450009
48
1.33
32,832,000
13
HLB
KR7028300002
822
1.26
31,030,500
14
LCB
KR7141080002
184
1.11
27,305,600
15
ABL Bio
KR7298380007
237
0.91
22,443,900
16
SKBP
KR7326030004
192
0.78
19,123,200
17
SCD
KR7000250001
98
0.78
19,208,000
18
HanmiPharm
KR7128940004
44
0.54
13,354,000
19
Hugel
KR7145020004
37
0.48
11,729,000
20
SKBS
KR7302440003
186
0.36
8,890,800
21
ST Pharm
KR7237690003
88
0.33
8,228,000
22
Celltrionph
KR7068760008
141
0.31
7,571,700
23
HANALL BIOPHARMA
KR7009420001
248
0.3
7,464,800
24
CLASSYS
KR7214150005
123
0.26
6,445,200
25
Hanmi Science
KR7008930000
143
0.25
6,084,650
26
SEEGENE
KR7096530001
225
0.23
5,771,250
27
GC Corp
KR7006280002
39
0.21
5,140,200
28
HK inno.N
KR7195940002
100
0.2
4,865,000
29
DAEWOONG PHARM
KR7069620003
32
0.18
4,400,000
30
MedyTox
KR7086900008
38
0.18
4,541,000
31
Pharmicell
KR7005690003
393
0.17
4,279,770
32
CHA Biotech
KR7085660009
375
0.16
3,956,250
33
L&C BIO
KR7290650001
117
0.15
3,615,300
34
Binex
KR7053030003
202
0.13
3,300,680
35
ShinpoongPharm
KR7019170000
232
0.12
2,934,800
36
EuBio
KR7206650004
219
0.12
2,998,110
37
WONTECH
KR7336570007
302
0.12
2,986,780
38
DENTIUM
KR7145720009
46
0.11
2,654,200
39
DongKook Pharm
KR7086450004
165
0.11
2,818,200
40
HLBPHARMA
KR7047920004
196
0.11
2,675,400
41
SD Biosensor
KR7137310009
245
0.1
2,501,450
42
BIONEER
KR7064550007
156
0.09
2,208,960
43
SELVAS AI
KR7108860008
166
0.09
2,151,360
44
BioPlus
KR7099430001
291
0.07
1,751,820
45
CUREXO
KR7060280005
204
0.07
1,701,360
46
Huons Global
KR7084110006
38
0.07
1,713,800
47
T&L
KR7340570001
32
0.07
1,721,600
Investment notice
- The information provided on this website is based on reliable sources, but its accuracy and completeness are not guaranteed.
- Financial investment products are not protected by the Korea Deposit Insurance Corporation in accordance with the Depositor Protection Act, and a loss of investment principal may occur, which belongs to the investor.
- Past performance does not guarantee future profits.
- In the case of a collective investment scheme that invests in foreign securities, asset values may be lost due to risks caused by market, political, and economic conditions in the target country.
- Derivatives may lose all or a significant portion of the investment principal in a short period of time due to high price volatility, and there is a risk that the counterparty may not be able to fulfill the terms of the contract when investing in over-the-counter derivatives.
- Before investing, be sure to read the investment prospectus and contract recommendation document regarding the investment subject, redemption method, and fee.
There are no products in the comparison box. Please include products to compare!